Posted by Michael Wonder on 29 May 2019
Sermonix receives FDA fast track designation for investigational drug lasofoxifene
28 May 2019 - Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have oestrogen receptor-positive metastatic breast cancer with an ESR1 mutation.
Sermonix Pharmaceuticals today announced that its lead investigational drug, lasofoxifene, has been granted fast track designation by the U.S. FDA.
Sermonix is currently engaged in a Phase 2 clinical study of lasofoxifene in oestrogen receptor-positive metastatic breast cancer.
